MedTrace Logo

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

NCT06365788 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2026-04-01

No results posted yet for this study

Summary

This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.

Conditions

  • Triple Negative Breast Neoplasms

Interventions

DRUG

Abemaciclib

150 mg tablet orally twice daily

DRUG

Bicalutamide

150 mg tablet orally once daily

Sponsors & Collaborators

  • Kom Op Tegen Kanker

    collaborator OTHER

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Teva Pharma

    collaborator INDUSTRY

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Patrick Neven, MD, PhD · Universitaire Ziekenhuizen KU Leuven

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-08
Primary Completion
2027-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06365788 on ClinicalTrials.gov